NASDAQ:EGLT - Egalet Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$0.44 -0.01 (-2.22 %)
(As of 06/24/2018 05:04 AM ET)
Previous Close$0.44
Today's Range$0.44 - $0.4619
52-Week Range$0.42 - $2.59
Volume260,534 shs
Average Volume395,861 shs
Market Capitalization$23.46 million
P/E Ratio-0.18
Dividend YieldN/A
Egalet logoEgalet Corporation, a specialty pharmaceutical company, develops, manufactures, and commercializes treatments for patients with pain and other conditions. It has licensed three approved pain products, such as SPRIX Nasal Spray, a non-steroidal anti-inflammatory drug indicated in adult patients for the short-term management of moderate to moderately severe pain that requires analgesia at the opioid level; OXAYDO, an immediate-release oxycodone product designed to discourage abuse via snorting for the management of acute and chronic pain severe enough to require an opioid analgesic, and for which alternative treatments are inadequate; and ARYMO ER, an extended-release (ER) morphine product formulated with abuse-deterrent (AD) properties for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. The company is also developing Egalet-002, a Guardian Technology AD, ER, oral oxycodone formulation, which is in Phase III clinical trials for the same indication as ARYMO ER. In addition, its other products include Egalet-003, an AD stimulant product candidate; and Egalet-004, an AD, ER hydrocodone-based product candidate. The company has a collaboration and license agreement with Acura Pharmaceuticals, Inc. to commercialize OXAYDO tablets; and Septodont, Inc. to promote SPRIX Nasal Spray. Egalet Corporation was founded in 2010 and is headquartered in Wayne, Pennsylvania.

Receive EGLT News and Ratings via Email

Sign-up to receive the latest news and ratings for EGLT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations


Debt-to-Equity Ratio-3.00
Current Ratio2.29
Quick Ratio2.24


Trailing P/E Ratio-0.18
Forward P/E Ratio-0.46
P/E GrowthN/A

Sales & Book Value

Annual Sales$26.14 million
Price / Sales0.89
Cash FlowN/A
Price / CashN/A
Book Value($0.86) per share
Price / Book-0.51


EPS (Most Recent Fiscal Year)($2.44)
Net Income$-69,350,000.00
Net Margins-208.90%
Return on EquityN/A
Return on Assets-57.93%


Outstanding Shares52,700,000

The Truth About Cryptocurrencies

Egalet (NASDAQ:EGLT) Frequently Asked Questions

What is Egalet's stock symbol?

Egalet trades on the NASDAQ under the ticker symbol "EGLT."

How were Egalet's earnings last quarter?

Egalet (NASDAQ:EGLT) announced its quarterly earnings results on Tuesday, May, 8th. The specialty pharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.29) by $0.03. The specialty pharmaceutical company had revenue of $6.26 million for the quarter, compared to analyst estimates of $8.10 million. View Egalet's Earnings History.

When is Egalet's next earnings date?

Egalet is scheduled to release their next quarterly earnings announcement on Wednesday, August, 8th 2018. View Earnings Estimates for Egalet.

What price target have analysts set for EGLT?

5 brokerages have issued twelve-month price objectives for Egalet's stock. Their forecasts range from $1.50 to $7.00. On average, they expect Egalet's share price to reach $4.1250 in the next twelve months. View Analyst Ratings for Egalet.

Who are some of Egalet's key competitors?

Who are Egalet's key executives?

Egalet's management team includes the folowing people:
  • Mr. Robert S. Radie, Pres, CEO & Director (Age 55)
  • Mr. Stanley J. Musial, Exec. VP, CFO & Sec. (Age 57)
  • Dr. Mark Strobeck, Exec. VP & COO (Age 47)
  • Ms. Barbara A. Carlin, Sr. VP & Chief Accounting Officer (Age 43)
  • Dr. Karsten Lindhardt M.Sc., Ph.D., Chief Scientific Officer (Age 46)

Has Egalet been receiving favorable news coverage?

Media stories about EGLT stock have trended somewhat positive recently, Accern reports. Accern rates the sentiment of news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Egalet earned a news impact score of 0.05 on Accern's scale. They also assigned news coverage about the specialty pharmaceutical company an impact score of 46.66 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.

How do I buy shares of Egalet?

Shares of EGLT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Egalet's stock price today?

One share of EGLT stock can currently be purchased for approximately $0.44.

How big of a company is Egalet?

Egalet has a market capitalization of $23.46 million and generates $26.14 million in revenue each year. The specialty pharmaceutical company earns $-69,350,000.00 in net income (profit) each year or ($2.44) on an earnings per share basis. Egalet employs 131 workers across the globe.

How can I contact Egalet?

Egalet's mailing address is 600 LEE ROAD SUITE 100, WAYNE PA, 19087. The specialty pharmaceutical company can be reached via phone at 610-833-4200 or via email at [email protected]

MarketBeat Community Rating for Egalet (EGLT)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  287 (Vote Outperform)
Underperform Votes:  159 (Vote Underperform)
Total Votes:  446
MarketBeat's community ratings are surveys of what our community members think about Egalet and other stocks. Vote "Outperform" if you believe EGLT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EGLT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/24/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.